TuneLab Connect
Access Lilly TuneLab Models: Federated AI for Smarter Drug Discovery
What if your team could access Lilly-developed AI models for small-molecule and antibody property prediction, while securely contributing to and benefiting from continuously improving federated models?
- Access high-value AI models: leverage Lilly TuneLab models for Small Molecule and Antibody property predictions, directly usable in your discovery workflows
- Operationalize AI across teams: TuneLab predictions are directly at hand for chemists and biologists in their research context within Signals secure cloud environment and the new software Signals Xynthetica for delivering Models-as-a-Service.
- Contribute and benefit from federated learning: share data securely, improve global model performance, and accelerate decision-making without compromising IP
Join us to explore how startups and biotechs can move from isolated models to scalable, collaborative AI that drives real impact in your drug discovery programs.
Revvity Signals Software Speakers
David Gosalvez, Ph.D.
Chief Strategy Officer at Revvity Signals
With 25 years of experience in scientific software and analytics, David Gosalvez brings a rare combination of technical and domain expertise with broad knowledge across scientific use cases. He is a passionate advocate for improving the efficiency and quality of science via innovative software solutions. As head of Product Strategy, David works with scientists and IT across pharma and chemical industry to set the direction of the Revvity Signals Informatics portfolio. He also works with other scientific software vendors to integrate complimentary capabilities and AI/ML models into our solutions. As Director of Cheminformatics, he was responsible for the sustained growth of ChemDraw and Spotfire Lead Discovery. Previously, David headed the interdisciplinary Science & Technology team chartered with creating the novel data management technologies that underpinned Revvity Signals platform. David also served as Executive Director of Application Development at CambridgeSoft where he brought to market the Oracle Chemistry Cartridge and ChemBioOffice Enterprise Suite.
Jon Gilbert, Ph.D.
Sr Director at Eli Lilly and Company
Jonathan Gilbert leads the growth of the Lilly TuneLab Ecosystem. Jonathan received his PhD from MIT in Chemical Engineering and has spent his last decade plus in biotech at multiple companies ranging from the Seed stage to early clinical public companies. Immediately prior to Lilly, Jonathan led Corporate Development and Strategy at Entact Bio.
Nicolas Triballeau, Ph.D.
Director, Drug Discovery Chemistry at Revvity Signals
Nicolas Triballeau is a Director of Drug Discovery Chemistry at Revvity Signals. With 17 years of experience in drug discovery, he has not only provided direct project support and led teams but has also played a significant role in establishing scientific standards and ontologies. Nicolas holds a master's degree in chemical engineering with a specialization in organic chemistry, a Pharm.D. and a Ph.D. in Drug Design from the University of Paris.